Last reviewed · How we verify

Metastatic carcinoma to colon — Treatment Landscape & Competitive Intelligence

Metastatic carcinoma to colon (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic carcinoma to colon, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bevacizumab Bevacizumab-Bvzr Roche Monoclonal antibody Vascular Endothelial Growth Factor (VEGF) 2004-01-01
Avastin bevacizumab Roche Vascular Endothelial Growth Factor Inhibitor [EPC] Vascular endothelial growth factor A 2004-01-01
Avastin Avastin Washington University School of Medicine Vascular endothelial growth factor A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche · 2 drugs in Metastatic carcinoma to colon
  2. Washington University School of Medicine · 1 drug in Metastatic carcinoma to colon

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic carcinoma to colon:

Cite this brief

Drug Landscape (2026). Metastatic carcinoma to colon — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-carcinoma-to-colon. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing